Prevents bronchospasm. ANDA 207625, held by Luoxin Aurovitas. Levalbuterol Hydrochloride.
As of Nov 16, 2026, ANDA 207625 (Levalbuterol Hydrochloride), held by Luoxin Aurovitas, was first approved by FDA on Dec 30, 2016, with 1 approved supplement and 0 published complete response letters.
Levalbuterol inhalation solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol inhalation solution is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 30, 2016 | Original application | Approved | None posted |
| Levalbuterol HydrochlorideEQ 0.0103% BASE · solution;inhalation | Levalbuterol Hydrochloride | Rx |
| Levalbuterol HydrochlorideEQ 0.021% BASE · solution;inhalation | Levalbuterol Hydrochloride | Rx |
| Levalbuterol HydrochlorideEQ 0.042% BASE · solution;inhalation | Levalbuterol Hydrochloride | Rx |
| Feb 6, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Dec 30, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters